How will HPV vaccines affect cervical cancer?

PubWeight™: 2.23‹?› | Rank: Top 2%

🔗 View Article (PMC 3181152)

Published in Nat Rev Cancer on October 01, 2006


Richard Roden1, T-C Wu

Author Affiliations

1: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA.

Associated clinical trials:

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers (Girasol) | NCT00925288

Comparison of Cervical Cancer Screening Tests in HIV-infected Women in Lusaka, Zambia | NCT02688816

Articles citing this

Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med (2008) 3.02

A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95

A pilot study of low-cost, high-resolution microendoscopy as a tool for identifying women with cervical precancer. Cancer Prev Res (Phila) (2012) 1.84

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70

Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer (2007) 1.48

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43

Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab (2010) 1.33

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14

Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12

HPV E6, E6AP and cervical cancer. BMC Biochem (2008) 1.08

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05

Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A (2009) 1.04

HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med (2010) 1.03

DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02

Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J Virol (2007) 1.02

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02

HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01

Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol (2009) 1.00

Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling. Curr Genomics (2009) 1.00

Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96

Role of L2 cysteines in papillomavirus infection and neutralization. Virol J (2009) 0.95

Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95

Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J (2010) 0.94

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94

Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92

Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types. J Infect Dis (2012) 0.91

Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90

Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol (2013) 0.90

Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90

DNA vaccines for cervical cancer. Am J Transl Res (2010) 0.88

DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett (2007) 0.87

Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland. Clin Vaccine Immunol (2008) 0.87

DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87

View and review on viral oncology research. Infect Agent Cancer (2010) 0.83

Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma. Infect Agent Cancer (2010) 0.83

Simultaneous detection, genotyping, and quantification of human papillomaviruses by multicolor real-time PCR and melting curve analysis. J Clin Microbiol (2012) 0.83

Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83

Detention of HPV L1 Capsid Protein and hTERC Gene in Screening of Cervical Cancer. Iran J Basic Med Sci (2013) 0.82

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One (2014) 0.82

A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81

Implications of tyrosine phosphoproteomics in cervical carcinogenesis. J Carcinog (2008) 0.81

Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland. Virol J (2009) 0.81

CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol (2010) 0.81

Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res (2009) 0.81

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag (2008) 0.81

Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79

Inhibitory effects of dobutamine on human gastric adenocarcinoma. World J Gastroenterol (2014) 0.79

Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J (2008) 0.79

Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology (2009) 0.79

Chlamydia induces anchorage independence in 3T3 cells and detrimental cytological defects in an infection model. PLoS One (2013) 0.79

Pediatricians are more supportive of the human papillomavirus vaccine than the general public. South Med J (2008) 0.78

Could the human papillomavirus vaccines drive virulence evolution? Proc Biol Sci (2015) 0.78

Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution. BMC Infect Dis (2017) 0.78

Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. PLoS One (2012) 0.77

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer (2016) 0.77

Cataracts in transgenic mice caused by a human papillomavirus type 18 E7 oncogene driven by KRT1-14. Exp Mol Pathol (2008) 0.77

A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays. Hum Vaccin Immunother (2015) 0.76

Human papillomavirus DNA detection in menstrual blood from patients with cervical intraepithelial neoplasia and condyloma acuminatum. J Clin Microbiol (2010) 0.76

A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology (2011) 0.76

Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia. Theor Biol Med Model (2012) 0.76

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci (2015) 0.76

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis (2016) 0.75

Dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron (2017) 0.75

LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter. Oncotarget (2016) 0.75

Background and Current Treatment of Squamous Cell Carcinoma of the Anus. Oncol Ther (2016) 0.75

Recognition of human oncogenic viruses by host pattern-recognition receptors. Front Immunol (2014) 0.75

Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. Int J Oncol (2017) 0.75

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75

Antitumor activity of dobutamine on human osteosarcoma cells. Oncol Lett (2016) 0.75

Association of the miR-17-5p variants with susceptibility to cervical cancer in a Chinese population. Oncotarget (2016) 0.75

Technological Microbiology: Development and Applications. Front Microbiol (2017) 0.75

Articles cited by this

(truncated to the top 100)

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46

Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46

The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43

Classification of papillomaviruses. Virology (2004) 14.16

The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57

Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61

Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80

A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09


Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72

A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet (2005) 7.09

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69

HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60

Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69

Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science (1992) 4.49

Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14

Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00

Mechanisms of human papillomavirus-induced oncogenesis. J Virol (2004) 3.95

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95

In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44

Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol (2002) 3.37

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11


Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 2.58

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53

Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52

The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology (2002) 2.49

Evaluating human papillomavirus vaccination programs. Emerg Infect Dis (2004) 2.47

Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44

Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 2.24

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis (2000) 2.24

Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21

Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med (2006) 2.10

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08

Solid cancers after bone marrow transplantation. J Clin Oncol (2001) 1.99

Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94

Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A (2000) 1.93

The promise of global cervical-cancer prevention. N Engl J Med (2005) 1.67

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology (1995) 1.65

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology (1994) 1.64

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59

Effect of local infection and oral contraception on immunoglobulin levels in cervical mucus. Infect Immun (1975) 1.59

Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 1.58

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol (1994) 1.57

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol (2001) 1.55

Papillomavirus DNA replication. Intervirology (1994) 1.54

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis (2005) 1.51

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol (2002) 1.47

Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst (1999) 1.38

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 1.38

The potential of human papillomavirus vaccines. N Engl J Med (2006) 1.35

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 1.34

Women's desired information about human papillomavirus. Cancer (2004) 1.32

Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines. J Virol (1991) 1.29

Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28

Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol (1993) 1.26

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25

Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol (1993) 1.23

HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology (1992) 1.21

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 1.20

Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. J Infect Dis (1992) 1.20

In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine (2005) 1.19

Chimeric papillomavirus-like particles. Virology (1997) 1.17

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine (2004) 1.17

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 1.16

Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec (1990) 1.15

Ethical analysis of HPV vaccine policy options. Vaccine (2006) 1.15

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology (1998) 1.15

A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology (1994) 1.15

Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol (1999) 1.13

From Papanicolaou to Bethesda: the rationale for a new cervical cytologic classification. Obstet Gynecol (1991) 1.13

HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 1.11

Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther (2006) 1.10

Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts. J Invest Dermatol (1972) 1.10

Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology (1995) 1.05

Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol (2000) 1.03

Animal models of human-papillomavirus-associated oncogenesis. Intervirology (1994) 1.02

Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology (2001) 1.00

Articles by these authors

(truncated to the top 100)

Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56

Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43

Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40

Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37

Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32

Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27

Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26

Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25

Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24

A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24

Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24

Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24

Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23

Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22

Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22

Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21

Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17

Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17

Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13

Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12

Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12

Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10

Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10

Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2012) 1.10

Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther (2006) 1.08

Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine (2007) 1.07

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04

Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother (2008) 1.04

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03

DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02

Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun (2008) 1.02

Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02

Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol J (2007) 1.02

Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01

HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01

Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01

Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther (2005) 1.01

DNA vaccines for cancer. IDrugs (2003) 1.00

Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res (2010) 0.99

Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99

Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res (2012) 0.99

MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension. AJNR Am J Neuroradiol (2008) 0.98

HPV DNA vaccines. Front Biosci (2003) 0.98

Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. J Biomed Opt (2007) 0.98

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol (2002) 0.98

In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci (2011) 0.97

Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther (2009) 0.97

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther (2003) 0.97

Molecular epidemiology of human papillomavirus. J Formos Med Assoc (2008) 0.97

Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96

Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene (2007) 0.96

Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96

Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95

Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine (2011) 0.95

Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci (2005) 0.95

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther (2008) 0.95

Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol (2009) 0.94

Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart (2005) 0.94

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94

Immune mechanism of the antitumor effects generated by bortezomib. J Immunol (2012) 0.93

Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer (2007) 0.93

Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92

Change in cerebral perfusion after carotid angioplasty with stenting is related to cerebral vasoreactivity: a study using dynamic susceptibility-weighted contrast-enhanced MR imaging and functional MR imaging with a breath-holding paradigm. AJNR Am J Neuroradiol (2009) 0.92

Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One (2012) 0.91

Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine (2008) 0.90

Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci (2014) 0.90

Preventative and therapeutic vaccines for cervical cancer. Expert Rev Vaccines (2003) 0.89

Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther (2003) 0.89

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci (2010) 0.89

Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res (2014) 0.89

Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther (2004) 0.89

Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther (2004) 0.89

Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene (2010) 0.88

DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine (2010) 0.88

Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther (2007) 0.87

Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer (2007) 0.87

Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand J Immunol (2008) 0.87

Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther (2008) 0.87

OGDHL is a modifier of AKT-dependent signaling and NF-κB function. PLoS One (2012) 0.87

Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70. Cancer Res (2007) 0.87

RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther (2008) 0.86

Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell Biosci (2012) 0.86